Literature DB >> 19947989

Differences in the clinical characteristics of Pneumocystis jirovecii pneumonia in immunocompromized patients with and without HIV infection.

Tatsuji Enomoto1, Arata Azuma, Ayumi Kohno, Kazuyo Kaneko, Hitoshi Saito, Minako Kametaka, Jiro Usuki, Akihiko Gemma, Shoji Kudoh, Seiichi Nakamura.   

Abstract

BACKGROUND AND
OBJECTIVE: The incidence of Pneumocystis jirovecii pneumonia (PCP) in patients with predisposing immunodeficiencies other than AIDS is growing. Knowing the different characteristics and outcomes of PCP according to HIV status would help physicians manage and treat patients with PCP.
METHODS: The medical charts of all patients with a proven first episode of PCP, diagnosed between 1997 and 2007 were retrospectively reviewed, and clinical and laboratory data abstracted.
RESULTS: Of the 35 patients with PCP, 18 were HIV-positive and 17 were HIV-negative with other immunosuppressive conditions. HIV-negative patients were significantly older than HIV-positive patients. The WCC (10 952 +/- 5669 vs 9750 +/- 3133/microL; P = 0.015), neutrophil counts (9631 +/- 5421 vs 5680 +/- 2628/microL; P = 0.01) and CD4+ lymphocyte counts (329 +/- 502 vs 47 +/- 50/microL; P < 0.001) were significantly higher in HIV-negative patients. Six of the 17 HIV-negative patients had a CD4+ lymphocyte count >300/microL. Serum IgG levels were lower in HIV-negative patients (943 +/- 379 vs 1635 +/- 657 mg/dL; P = 0.017). Mortality was higher in HIV-negative (52.9%) than in HIV-positive patients (0%). On univariate analysis, risk factors for mortality from PCP were the presence of underlying pulmonary disease (odds ratio 4.000, 95% CI: 1.501-10.658) and HIV-negative status (odds ratio 2.125, 95% CI: 1.283-3.518).
CONCLUSIONS: The characteristics and outcomes of PCP differ significantly depending on HIV status. The existence of underlying pulmonary diseases may be associated with the prognosis of HIV-negative patients with PCP.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19947989     DOI: 10.1111/j.1440-1843.2009.01660.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  24 in total

1.  Underlying renal insufficiency: the pivotal risk factor for Pneumocystis jirovecii pneumonia in immunosuppressed patients with non-transplant glomerular disease.

Authors:  Wen-Ling Ye; Nan Tang; Yu-Bing Wen; Hang Li; Min-Xi Li; Bin Du; Xue-Mei Li
Journal:  Int Urol Nephrol       Date:  2016-06-28       Impact factor: 2.370

Review 2.  Colonization by Pneumocystis jirovecii and its role in disease.

Authors:  Alison Morris; Karen A Norris
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

3.  Pneumocystis jiroveci pneumonia in giant cell arteritis: A case series.

Authors:  Tanaz A Kermani; Steven R Ytterberg; Kenneth J Warrington
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-05       Impact factor: 4.794

4.  Combine use of glucocorticoid with other immunosuppressants is a risk factor for Pneumocystis jirovecii pneumonia in autoimmune inflammatory disease patients: a meta-analysis.

Authors:  Huyu Wang; Lili Shui; Yajuan Chen
Journal:  Clin Rheumatol       Date:  2022-09-23       Impact factor: 3.650

5.  Pneumocystis pneumonia in a non-HIV patient on chronic corticosteroid therapy: a question of prophylaxis.

Authors:  Michael J Plakke; Leena Jalota; Benjamin J Lloyd
Journal:  BMJ Case Rep       Date:  2013-03-01

6.  Detection of Pneumocystis jirovecii by Quantitative PCR To Differentiate Colonization and Pneumonia in Immunocompromised HIV-Positive and HIV-Negative Patients.

Authors:  T Fauchier; L Hasseine; M Gari-Toussaint; V Casanova; P M Marty; C Pomares
Journal:  J Clin Microbiol       Date:  2016-03-23       Impact factor: 5.948

Review 7.  Pneumocystis jirovecii Pneumonia in Rheumatoid Arthritis Patients: Risks and Prophylaxis Recommendations.

Authors:  Shunsuke Mori; Mineharu Sugimoto
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2015-09-06

8.  Risk Factors of Mortality From Pneumocystis Pneumonia in Non-HIV Patients: A Meta-Analysis.

Authors:  Yuqiong Wang; Xiaoyi Zhou; Maidinuer Saimi; Xu Huang; Ting Sun; Guohui Fan; Qingyuan Zhan
Journal:  Front Public Health       Date:  2021-06-16

9.  Epidemiological and clinical characteristics of immunocompromised patients infected with Pneumocystis jirovecii in a twelve-year retrospective study from Norway.

Authors:  Stine Grønseth; Tormod Rogne; Raisa Hannula; Bjørn Olav Åsvold; Jan Egil Afset; Jan Kristian Damås
Journal:  BMC Infect Dis       Date:  2021-07-07       Impact factor: 3.090

Review 10.  Pneumocystis jirovecii infection: an emerging threat to patients with rheumatoid arthritis.

Authors:  Shunsuke Mori; Mineharu Sugimoto
Journal:  Rheumatology (Oxford)       Date:  2012-09-22       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.